Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Axsome Therapeutics (NASDAQ:AXSM) had its price target lifted by Robert W. Baird from $132.00 to $160.00 in a research note released on Monday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts have also recently commented on the stock. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday, February 10th. Truist Financial upped their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Needham & Company LLC raised their target price on Axsome Therapeutics from $133.00 to $153.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Wells Fargo & Company raised their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $167.36.

Axsome Therapeutics Trading Down 0.3 %

Shares of Axsome Therapeutics stock opened at $127.15 on Monday. The firm has a fifty day moving average price of $105.00 and a 200 day moving average price of $96.52. The stock has a market cap of $6.20 billion, a PE ratio of -21.23 and a beta of 1.05. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million during the quarter, compared to analysts’ expectations of $117.83 million. Equities research analysts predict that Axsome Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Raiffeisen Bank International AG purchased a new position in Axsome Therapeutics during the 4th quarter worth $51,000. Assetmark Inc. purchased a new stake in Axsome Therapeutics in the 4th quarter valued at approximately $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics in the 4th quarter valued at about $64,000. Aquatic Capital Management LLC acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $76,000. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Axsome Therapeutics during the 4th quarter worth $86,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.